Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 301,929
  • Shares Outstanding, K 17,834
  • Annual Sales, $ 16,130 K
  • Annual Income, $ -20,820 K
  • 60-Month Beta 2.17
  • Price/Sales 18.64
  • Price/Cash Flow N/A
  • Price/Book 3.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/20
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate 0.53
  • Low Estimate -0.63
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.84 +56.18%
on 11/15/19
17.15 -1.28%
on 12/13/19
+5.82 (+52.39%)
since 11/13/19
3-Month
9.86 +71.70%
on 10/09/19
17.15 -1.28%
on 12/13/19
+1.67 (+10.94%)
since 09/13/19
52-Week
9.86 +71.70%
on 10/09/19
34.92 -51.52%
on 03/14/19
-6.46 (-27.62%)
since 12/13/18

Most Recent Stories

More News
KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema

--- Pre-Planned Analyses Show Clinical Benefit on Vision -

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

--- KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected This Month -

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals Provides Business Update

--- KVD001 Phase 2 Clinical Trial Data for Patients with Diabetic Macular Edema (DME) Expected This Quarter -

KALV : 16.93 (+0.42%)
KalVista Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KALV : 16.93 (+0.42%)
KalVista Group Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KALV : 16.93 (+0.42%)
KalVista Pharmaceuticals Reports Fiscal First Quarter Results

--- KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected in Q4 2019 -

KALV : 16.93 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade KALV with:

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

2nd Resistance Point 17.62
1st Resistance Point 17.27
Last Price 16.93
1st Support Level 16.46
2nd Support Level 16.00

See More

52-Week High 34.92
Fibonacci 61.8% 25.35
Fibonacci 50% 22.39
Fibonacci 38.2% 19.43
Last Price 16.93
52-Week Low 9.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar